EASD 2019 The CAROLINA trial compared CV safety of linagliptin and glimepiride in patients with T2DM and found comparable CV safety, but higher risk of hypoglycemia with glimepiride.
EASD 2019 Both HF patients with and without T2DM showed about 25% reduction of worsening HF and CV death when treated with dapagliflozin in the DAPA-HF study, and symptoms improved.
EASD 2019 The VERIFY trial demonstrated that early combination therapy using vildagliptin and metformin was superior to a sequential approach involving later intensification in new T2DM
ESC 2019 The THEMIS study evaluated the effect of ticagrelor vs. placebo on top of aspirin in diabetes patients with stable coronary artery disease. Netto clinical benefit depended on having a history of PCI or not.
ESC 2019 As a consequence of recent outcome trials of new therapies for diabetes, new treatment recommendations now include use of SGLT2 inhibitors and GLP-1RA.
ESC 2019 Addition of ticagrelor to aspirin resulted in a reduction of CV outcomes in CAD patients with diabetes, but at the expense of increased bleeding. Net clinical benefit was favorable in those with previous PCI.
ESC 2019 In diabetes patients with stable CAD, ticagrelor plus aspirin resulted in reduced CV outcomes, but at the cost of increased bleeding. Net clinical benefit was favorable in a prespecified subgroup of patients with prior PCI.
Prof. Knop describes the possible mechanisms of CV/CKD risk reduction by GLP-1 receptor activation.
Prof. Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.
A posthoc, exploratory analysis of Look AHEAD data shows that the treatment effect of an intensive lifestyle intervention on the occurrence of MACE varies greatly between patients.
In the phase III DAPA-HF trial, treatment with an SGLT2 inhibitor resulted in reduction in the primary composite endpoint of CV death or worsening of HF in patients with HFrEF compared to placebo.
Frederik Persson shows evidence of renoprotective effects with GLP-1RA treatment, by discussing various small clinical trials as well as CVOTs with GLP-1RAs.